Your browser is no longer supported. Please, upgrade your browser.
GTHX [NASD]
G1 Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.90 Insider Own0.70% Shs Outstand38.01M Perf Week18.42%
Market Cap794.25M Forward P/E- EPS next Y-3.91 Insider Trans-11.01% Shs Float34.07M Perf Month7.93%
Income-109.30M PEG- EPS next Q-0.87 Inst Own90.90% Short Float21.59% Perf Quarter56.85%
Sales28.70M P/S27.67 EPS this Y-27.60% Inst Trans-4.82% Short Ratio5.81 Perf Half Y9.11%
Book/sh5.20 P/B4.01 EPS next Y-38.70% ROA-41.50% Target Price- Perf Year-19.29%
Cash/sh6.25 P/C3.33 EPS next 5Y- ROE-49.40% 52W Range8.80 - 26.69 Perf YTD15.79%
Dividend- P/FCF- EPS past 5Y-65.60% ROI- 52W High-21.97% Beta2.43
Dividend %- Quick Ratio7.50 Sales past 5Y- Gross Margin- 52W Low136.70% ATR1.10
Employees104 Current Ratio7.50 Sales Q/Q- Oper. Margin- RSI (14)65.30 Volatility6.74% 5.12%
OptionableYes Debt/Eq0.10 EPS Q/Q64.40% Profit Margin- Rel Volume0.66 Prev Close20.67
ShortableYes LT Debt/Eq0.10 EarningsNov 04 AMC Payout- Avg Volume1.27M Price20.83
Recom1.70 SMA209.40% SMA5024.13% SMA20029.30% Volume836,519 Change0.77%
Nov-17-20Downgrade Raymond James Strong Buy → Outperform
Jun-26-20Initiated ROTH Capital Buy $55
Jan-21-20Reiterated H.C. Wainwright Buy $72 → $82
Aug-08-19Upgrade JP Morgan Neutral → Overweight
Feb-07-19Initiated B. Riley FBR Buy $55
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Dec-20-18Initiated Raymond James Strong Buy
Nov-08-18Reiterated Needham Buy $76 → $74
Sep-10-18Resumed BTIG Research Buy $80
May-29-18Initiated H.C. Wainwright Buy $61
May-18-18Reiterated Needham Buy $42 → $60
Jan-11-21 06:30AM  
Jan-05-21 07:00AM  
Jan-04-21 07:00AM  
Dec-31-20 11:57PM  
Dec-14-20 09:56AM  
Dec-09-20 05:00PM  
Nov-30-20 10:30AM  
Nov-29-20 12:30PM  
Nov-24-20 07:00AM  
Nov-18-20 07:00AM  
Nov-15-20 08:18AM  
Nov-11-20 07:01AM  
Nov-08-20 07:56AM  
Nov-05-20 08:39AM  
Nov-04-20 09:32PM  
04:31PM  
04:01PM  
02:30PM  
Oct-28-20 07:01AM  
Oct-15-20 07:00AM  
Sep-30-20 04:01PM  
Sep-14-20 07:00AM  
Sep-02-20 07:01AM  
Aug-17-20 06:00AM  
Aug-05-20 04:01PM  
Aug-04-20 07:00AM  
Aug-03-20 07:00AM  
Jul-29-20 07:01AM  
Jul-23-20 08:25AM  
Jul-22-20 06:00PM  
Jun-30-20 04:36PM  
04:10PM  
Jun-22-20 06:00AM  
Jun-18-20 12:27PM  
Jun-16-20 07:09AM  
Jun-11-20 08:36AM  
Jun-01-20 04:01PM  
May-13-20 05:31PM  
May-07-20 10:30AM  
May-06-20 04:01PM  
07:36AM  
Apr-29-20 07:00AM  
Apr-07-20 07:00AM  
Mar-13-20 07:12AM  
Mar-12-20 08:05AM  
Feb-26-20 04:01PM  
Feb-24-20 02:59PM  
07:00AM  
Feb-19-20 07:00AM  
Feb-18-20 07:00AM  
Feb-17-20 07:00AM  
Feb-06-20 07:00AM  
Jan-14-20 09:01AM  
07:00AM  
Jan-07-20 07:00AM  
Dec-11-19 06:00PM  
Nov-26-19 07:00AM  
Nov-21-19 09:44AM  
Nov-12-19 07:00AM  
Nov-08-19 08:49AM  
Nov-07-19 06:07AM  
Nov-05-19 04:00PM  
Oct-29-19 07:00AM  
Oct-27-19 08:14PM  
Sep-30-19 01:13PM  
Sep-29-19 06:00AM  
Sep-28-19 04:15AM  
Sep-10-19 06:01AM  
Sep-03-19 07:00AM  
Aug-28-19 07:27AM  
Aug-08-19 12:42AM  
Aug-07-19 04:01PM  
Aug-06-19 07:00AM  
Jul-31-19 07:00AM  
Jul-30-19 07:01AM  
Jul-18-19 08:22AM  
Jun-28-19 07:56PM  
Jun-23-19 09:00AM  
Jun-19-19 01:58PM  
12:30PM  
09:48AM  
Jun-18-19 04:33PM  
03:14PM  
06:00AM  
Jun-14-19 07:01AM  
Jun-13-19 07:01AM  
Jun-11-19 07:00AM  
Jun-01-19 04:00PM  
May-19-19 09:29PM  
May-16-19 07:00AM  
May-13-19 01:12PM  
07:00AM  
May-12-19 09:04AM  
May-09-19 04:01PM  
May-05-19 08:15PM  
May-02-19 07:00AM  
May-01-19 02:15PM  
Apr-30-19 03:21PM  
02:28PM  
08:06AM  
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2 clinical trials for patients with extensive-stage small cell lung cancer(SCLC), as well as Phase 2 clinical trial for patients with first-line (SCLC) and metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase 1b/2a clinical trials for the treatment of breast cancer and in Phase 1b clinical trial for non-small cell lung cancer; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase I/2 clinical trial. G1 Therapeutics, Inc. has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RUDNICK SETHDirectorDec 24Sale20.1092418,5725,266Dec 29 04:50 PM
RUDNICK SETHDirectorDec 23Sale20.1813,118264,7576,190Dec 23 06:54 PM
RUDNICK SETHDirectorDec 22Sale20.3318,974385,70219,308Dec 23 06:54 PM
Velleca Mark A.President and CEODec 17Option Exercise3.7210,00037,20047,000Dec 17 06:01 PM
Velleca Mark A.President and CEODec 17Sale19.9710,000199,66837,000Dec 17 06:01 PM
Velleca Mark A.President and CEODec 16Option Exercise3.7210,00037,20047,000Dec 17 06:01 PM
Velleca Mark A.President and CEODec 16Sale19.2010,000192,02137,000Dec 17 06:01 PM
Velleca Mark A.President and CEODec 15Option Exercise3.7210,00037,20047,000Dec 17 06:01 PM
Velleca Mark A.President and CEODec 15Sale19.4310,000194,29737,000Dec 17 06:01 PM
Malik RajeshCh. Medical Officer & SVP R&DDec 10Option Exercise4.179,00037,53038,200Dec 11 04:50 PM
Malik RajeshCh. Medical Officer & SVP R&DDec 10Sale20.069,000180,55029,200Dec 11 04:50 PM
RUDNICK SETHDirectorDec 10Sale20.0054610,92138,282Dec 10 05:30 PM
RUDNICK SETHDirectorDec 09Sale20.325,773117,28438,828Dec 10 05:30 PM
RUDNICK SETHDirectorDec 08Sale20.1913,161265,69444,601Dec 10 05:30 PM
RUDNICK SETHDirectorDec 01Sale20.0952010,44957,762Dec 03 04:20 PM
MUIR GLENN PDirectorNov 18Buy13.5050,000675,000170,969Nov 19 04:54 PM
Bailey John E. (Jack) Jr.DirectorNov 11Buy12.834,00051,3208,000Nov 13 04:33 PM
Bailey John E. (Jack) Jr.DirectorNov 10Buy12.764,00051,0554,000Nov 13 04:33 PM
Hanson James S.General CounselSep 04Buy14.951,00014,9504,000Sep 08 08:38 PM
Malik RajeshCh. Medical Officer & SVP R&DMar 13Option Exercise0.392,50097529,200Mar 16 07:00 AM
Moses Jennifer K.CFOMar 13Option Exercise3.722,0007,44011,000Mar 16 07:00 AM
Velleca Mark A.President and CEOMar 13Option Exercise0.393,0001,17037,000Mar 16 07:00 AM
Moses Jennifer K.CFOJan 23Option Exercise3.721,0003,7209,000Jan 24 04:58 PM
Velleca Mark A.President and CEOJan 23Option Exercise0.396,0002,34034,000Jan 24 04:59 PM
Malik RajeshCh. Medical Officer & SVP R&DJan 23Option Exercise0.395,0001,95026,700Jan 24 04:58 PM